Key result
Obese women with PCOS were significantly more insulin resistant than obese controls (P=0.02), whereas normal-weight women with PCOS had similar insulin sensitivity to normal-weight controls.
Why the study?
Does polycystic ovary syndrome independently impair metabolic and microvascular insulin sensitivity in normal-weight and obese women?
Case-Control (n=62)
Does polycystic ovary syndrome independently impair metabolic and microvascular insulin sensitivity in normal-weight and obese women?
p-value: p=0.02
PCOS aggravates metabolic insulin resistance in obese women but does not independently impair insulin sensitivity in normal-weight women, suggesting obese PCOS patients are at particularly increased cardiometabolic risk.
No takes yet. Share an insight, caveat, or question.
Supports intensified cardiometabolic monitoring in obese PCOS; hypothesis-generating for independent effects in normal-weight women.
Ketel et al. (2008) conducted a case-control in Polycystic ovary syndrome and obesity (n=62). Polycystic ovary syndrome vs. Age- and BMI-matched controls without PCOS was evaluated on Metabolic insulin sensitivity (M/I value) and microvascular insulin sensitivity (ACh and SNP responses) (p=0.02). Obese women with PCOS were significantly more insulin resistant than obese controls (P=0.02), whereas normal-weight women with PCOS had similar insulin sensitivity to normal-weight controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: